Bladder Cancer
April 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Bladder Cancer abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Bladder Cancer. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Bladder Cancer. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Bladder Cancer every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Authors:Bellmunt J, Powles T, Vogelzang NJ
Institution:Bladder Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States; PSMAR-IMIM Lab, Barcelona, Spain. Electronic address: Joaquim_bellmunt@DFCI.HARVARD.edu.
Journal:Cancer Treat Rev. 2017 Mar;54:58-67. doi: 10.1016/j.ctrv.2017.01.007. Epub 2017 Feb 2.

2:Acid-base disorders after orthotopic bladder replacement: comparison of an ileal neobladder and an ileal conduit.
Authors:Cho A, Lee SM, Noh JW, Choi DK, Lee Y, Cho ST, Kim KK, Lee YG, Lee YK
Institution:a Division of Nephrology, Department of Internal Medicine. College of Medicine, Kangnam Sacred Heart Hospital , Seoul , Korea. College of Medicine, Kangnam Sacred Heart Hospital , Seoul , Korea. College of Medicine, Kangnam Sacred Heart Hospital , Seoul , Korea. College of Medicine, Kangnam Sacred Heart Hospital , Seoul , Korea. College of Medicine, Kangnam Sacred Heart Hospital , Seoul , Korea.
Journal:Ren Fail. 2017 Nov;39(1):379-384. doi: 10.1080/0886022X.2017.1287733.

3:The Influence of Tumor Size on Oncologic Outcomes for Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy.
Authors:Su X, Fang D, Li X, Xiong G, Zhang L, Hao H, Gong Y, Zhang Z, Zhou L
Institution:Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. Peking University, National Urological Cancer Center, Beijing 100034, China.
Journal:Biomed Res Int. 2016;2016:4368943. doi: 10.1155/2016/4368943. Epub 2016 Dec 14.

4:Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review.
Authors:Sanguedolce F, Loizzi D, Sollitto F, Di Bisceglie M, Lucarelli G, Carrieri G, Bufo P, Cormio L
Institution:Department of Pathology, University Hospital, Foggia, Italy.
Journal:Oncology. 2017;92(3):125-134. doi: 10.1159/000454731. Epub 2017 Jan 6.

5:Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
Authors:Patel R, Bock M, Polotti CF, Elsamra S
Institution:a Division of Urology , Rutgers Robert Wood Johnson Medical School , New Brunswick , NJ , USA. Brunswick , NJ , USA. Brunswick , NJ , USA. Brunswick , NJ , USA. Robert Wood Johnson Medical School , New Brunswick , NJ , USA.
Journal:Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):225-232. doi: 10.1080/17425255.2017.1277204. Epub 2017 Jan 11.

6:Predicting Survival After Irradiation of Metastases from Transitional Carcinoma of the Bladder.
Authors:Manig L, Kasmann L, Janssen S, Rades D
Institution:Department of Radiation Oncology, University of Lubeck, Lubeck, Germany. LKaesmann@gmail.com.
Journal:Anticancer Res. 2016 Dec;36(12):6663-6665.

7:A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival.
Authors:Hancock BM, McGuire KL, Tsuji S, Reil K, Hernandez V, Giacalone MJ, Godbey WT
Institution:Department of Cell & Molecular Biology, San Diego State University, San Diego, CA, U.S.A. CA, U.S.A. Orleans, LA, U.S.A. Godbey@Tulane.edu.
Journal:Anticancer Res. 2016 Dec;36(12):6243-6248.

8:SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).
Authors:Lazaro M, Gallardo E, Domenech M, Pinto A, Del Alba AG, Puente J, Fernandez O, Font A, Lainez N, Vazquez S
Institution:Medical Oncology Department, Hospital Alvaro Cunqueiro-Complexo Hospitalario Universitario de Vigo, Estrada Clara Campoamor, 34136312, Vigo, Spain. martin.lazaro.quintela@sergas.es. Spain. Manresa, Manresa, Spain. Mallorca, Spain. Spain.
Journal:Clin Transl Oncol. 2016 Dec;18(12):1197-1205. Epub 2016 Nov 29.

9:Risk factors for development of primary bladder squamous cell carcinoma.
Authors:Manley KV, Hubbard R, Swallow D, Finch W, Wood SJ, Biers SM
Institution:Norfolk and Norwich University Hospitals NHS Foundation Trust , UK.
Journal:Ann R Coll Surg Engl. 2017 Feb;99(2):155-160. doi: 10.1308/rcsann.2016.0343. Epub 2016 Nov 21.

10:Urological complications after cystectomy as part of pelvic exenteration are higher than that after cystectomy for primary bladder malignancy.
Authors:Brown KG, Solomon MJ, Latif ER, Koh CE, Vasilaras A, Eisinger D, Sved P
Institution:Surgical Outcomes Research Centre (SOuRCe), Sydney Local Health District, Sydney, Australia. Australia. Australia. Australia. Australia.
Journal:J Surg Oncol. 2017 Mar;115(3):307-311. doi: 10.1002/jso.24511. Epub 2016 Nov 18.

11:Elevated preoperative plasma fibrinogen level is an independent predictor of malignancy and advanced stage disease in patients with bladder urothelial tumors.
Authors:Liu J, Li D, Cao L, Wang Z, Li Y, Liu H, Chen G
Institution:Department of Urology, Jinshan Hospital of Fudan University, Shanghai City, 201508, PR China. Province, 250012, PR China. Province, 250012, PR China. 201508, PR China. Province, 250012, PR China. Province, 250012, PR China. 201508, PR China. Electronic address: chengang305@163.com.
Journal:Int J Surg. 2016 Dec;36(Pt A):249-254. doi: 10.1016/j.ijsu.2016.11.010. Epub 2016 Nov 5.

12:Diagnostic value of positive urinary cytology in the detection of recurrent urothelial carcinoma: 10-Year Experience at the Papanicolaou Cytology Laboratory.
Authors:Shanmugam V, Geraghty B, DeSimone RA, Hoda RS
Institution:Papanicolaou Cytology Laboratory, Department of Pathology & Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York. New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York. New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York. New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York.
Journal:Diagn Cytopathol. 2016 Dec;44(12):975-979. doi: 10.1002/dc.23598. Epub 2016 Sep 26.

13:Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
Authors:Alongi P, Caobelli F, Gentile R, Stefano A, Russo G, Albano D, Baldari S, Gilardi MC, Midiri M
Institution:Department of Radiological Sciences, Nuclear Medicine Unit, San Raffaele G. Giglio Institute, Contrada Pietrapollastra-Pisciotto, 90015, Cefalu, Italy. alongi.pierpaolo@gmail.com. Functional Images, University of Messina, Messina, Italy. Palermo, Italy. Functional Images, University of Messina, Messina, Italy. Giglio Institute, Contrada Pietrapollastra-Pisciotto, 90015, Cefalu, Italy. Palermo, Italy.
Journal:Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):224-233. doi: 10.1007/s00259-016-3500-8. Epub 2016 Aug 26.

14:The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Authors:Murasawa H, Koie T, Ohyama C, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Iwabuchi I, Ogasawara M, Kawaguchi T
Institution:Department of Urology, Hirosaki University, Graduate School of Medicine, 5 Zaifucho, Hirosaki, 036-8562, Japan. Zaifucho, Hirosaki, 036-8562, Japan. goodwin@hirosaki-u.ac.jp. Zaifucho, Hirosaki, 036-8562, Japan. Zaifucho, Hirosaki, 036-8562, Japan. Zaifucho, Hirosaki, 036-8562, Japan. Zaifucho, Hirosaki, 036-8562, Japan. Zaifucho, Hirosaki, 036-8562, Japan. Zaifucho, Hirosaki, 036-8562, Japan. 2-1-1, Aomori, Japan. 2-1-1, Aomori, Japan. 2-1-1, Aomori, Japan.
Journal:Int J Clin Oncol. 2017 Feb;22(1):159-165. doi: 10.1007/s10147-016-1029-2. Epub 2016 Aug 17.

For a FREE PREVIEW of the Medifocus Guidebook on Bladder Cancer click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Bladder Cancer click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Bladder Cancer...
at a Special 20% Discount


Medifocus Guidebook on Bladder Cancer

Updated: January 29, 2017
177 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Bladder Cancer is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

BC52405210

Coupon Expires: May 25, 2017



What Our Customers Are Saying...

"My father, a veterinarian, was recently diagnosed with invasive bladder cancer. In wondering how best to support him, I decided to gift him a copy of the MediFocus Guidebook on Bladder Cancer. I knew it would appeal to his "scientific side". I wrote a loving and personal message in the Guide to remind him how much I loved him and then gave it to him. After reading the Guide, he took it to his Urologist and was able to generate excellent and candid questions about his condition."
R.R.
Modesto, California


"This Medifocus Guidebook was significantly helpful at a time that we needed information quickly. We felt we gained information that offered us insight on what to ask our physician, as well as a preview of options on treatment and risk factors that he would probably discuss with us. Emotionally, it's a 'god-send' to look up and receive information immediately. Thanks."
L.H.S.
Crestview, Florida



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.